VYNE Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 15. Exhibits and Financial Statement Schedules
(a)Documents Filed as Part of This Report
- Financial statements.
See Index to Financial Statements under Item 8 of Part II of this Annual Report, which is incorporated herein by reference.
- Financial statement schedules.
No schedules are applicable or required, or the information is included in the consolidated financial statements or notes thereto.
- Exhibits. See Item 15(b) below.
(b)Exhibits
| Incorporation by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number · Description Of Document · Form · SEC File No. · Exhibit · Filing Date · Filed Herewith | |||||
| 2.1(a)^ | Agreement and Plan of Merger and Reorganization, dated December 17, 2025, by and among VYNE Therapeutics Inc., Yarrow Bioscience, Inc., and Yellow Merger Sub Corp.* | 8-K | 001-38356 | 2.1 | December 17, 2025 |
| 2.1(b) | Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated January 30, 2026. | 8-K | 001-38356 | 10.1 | January 30, 2026 |
| 3.1(a) | Amended and Restated Certificate of Incorporation. | 10-K | 001-38356 | 3.1 | March 17, 2022 |
| 3.1(b) | Certificate of Amendment to the Amended and Restated Certificate of Incorporation. | 8-K | 001-38356 | 3.1 | February 10, 2023 |
| 3.2 | Amended and Restated Bylaws. | 10-Q | 001-38356 | 3.2 | November 14, 2022 |
| 4.1 | Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934. | 10-K | 001-38356 | 4.1 | March 14, 2023 |
| 4.2 | Second Amended and Restated Warrant, by and among VYNE Therapeutics Inc. and Perceptive Credit Holdings II, LP. | 10-Q | 001-38356 | 4.1 | May 11, 2020 |
| 4.3 | Second Amended and Restated Warrant, by and among VYNE Therapeutics Inc. and Orbimed Royalty & Credit Opportunities III, LP. | 10-Q | 001-38356 | 4.2 | May 11, 2020 |
| 4.4 | Form of Pre-Funded Warrant to Purchase Common Stock. | 8-K | 001-38356 | 4.1 | October 30, 2023 |
| 10.1†* | License Agreement (Topical), dated as of August 9, 2021, by and between In4Derm Limited and VYNE Therapeutics Inc. | 10-Q | 001-38356 | 10.1 | November, 10, 2021 |
| 10.2†* | License Agreement (Oral), dated as of April 28, 2023, by and between Tay Therapeutics and VYNE Therapeutics Inc. | 10-Q | 001-38356 | 10.1 | August 14, 2023 |
| 10.3 | Sales Agreement, dated as of March 1, 2024, by and between VYNE Therapeutics Inc. and Cowen and Company, LLC. | 10-K | 001-38356 | 10.3 | March 1, 2024 |
| 10.4# | 2009 Israeli Share Option Plan. | F-1/A | 001-36621 | 10.1 | September 3, 2014 |
| 10.5(a)# | 2011 Stock Incentive Plan, as amended. | S-1 | 001-38356 | 10.4(a) | December 28, 2017 |
| 10.5(b)# | Amendment to 2011 Stock Incentive Plan. | S-1 | 001-38356 | 10.4(b) | December 28, 2017 |
| 10.5(c)# | Form of Stock Option Agreement under 2011 Stock Incentive Plan. | S-1 | 001-38356 | 10.4(c) | December 28, 2017 |
| 10.5(d)# | Form of Immediately Exercisable Stock Option Agreement under 2011 Stock Incentive Plan. | S-1 | 001-38356 | 10.4(d) | December 28, 2017 |
| 10.6# | 2015 Israeli Share Incentive Plan. | F-3 | 001-36621 | 10.2 | October 21, 2015 |
| 10.7(a)# | 2018 Omnibus Incentive Plan. | S-1/A | 001-38356 | 10.5(a) | January 12, 2018 |
| 10.7(b)# | Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan. | S-1/A | 001-38356 | 10.5(b) | January 12, 2018 |
| 10.7(c)# | Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan. | 10-K | 001-38356 | 10.11(c) | March 4, 2021 |
| 10.8(a)# | 2019 Equity Incentive Plan. | 10-Q | 001-38356 | 10.5 | May 11, 2020 |
| 10.8(b)# | Form of Share Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan for U.S. and Israeli Employees. | 10-Q | 001-38356 | 10.8 | May 11, 2020 |
| 10.8(c)# | Form of Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the 2019 Equity Incentive Plan for U.S. and Israeli Employees. | 10-Q | 001-38356 | 10.9 | May 11, 2020 |
| 10.9# | 2019 Employee Share Purchase Plan. | 10-Q | 001-38356 | 10.10 | May 11, 2020 |
| 10.10# | Offer Letter, dated as of March 25, 2020, by and between VYNE Pharmaceuticals Inc. and David Domzalski. | 10-Q | 001-38356 | 10.13 | May 11, 2020 |
| 10.11# | Offer Letter, dated as of April 7, 2021, by and between VYNE Pharmaceuticals Inc. and Mutya Harsch. | 10-Q | 001-38356 | 10.2 | May 6, 2021 |
| 10.12# | Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart. | 10-K | 001-38356 | 10.12 | March 17, 2022 |
| 10.13# | Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda. | 10-K | 001-38356 | 10.13 | March 17, 2022 |
| 10.14 | Form of Securities Purchase Agreement, dated as of October 27, 2023, by and among VYNE Therapeutics Inc. and the Purchasers. | 8-K | 001-38356 | 10.1 | October 30, 2023 |
| 10.15 | Form of Registration Rights Agreement, dated as of October 27, 2023, by and among VYNE Therapeutics Inc. and the Purchasers. | 8-K | 001-38356 | 10.2 | October 30, 2023 |
| 10.16(a)# | VYNE Therapeutics Inc. 2023 Equity Incentive Plan. | 8-K | 001-38356 | 10.1 | December 13, 2023 |
| 10.16(b)# | Form of Director Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan | 8-K | 001-38356 | 10.2 | December 13, 2023 |
| 10.16(c)# | Form of Employee Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan. | 8-K | 001-38356 | 10.3 | December 13, 2023 |
| 10.16(d)# | Form of Employee Restricted Share Unit Grant Notice and Restricted Share Unit Award Agreement under the 2023 Equity Incentive Plan. | 8-K | 001-38356 | 10.4 | December 13, 2023 | |
| 10.17# | Non-Employee Director Compensation Policy. | 10-K | 001-38356 | 10.17 | March 1, 2024 | |
| 10.18 | First amendment to VYNE Therapeutics Inc. 2023 Equity Incentive Plan | 8-K | 001-38356 | 10.1 | December 12, 2024 | |
| 10.19†* | Amendment to License Agreement (Topical) dated as February 12, 2025, by and between Tay Therapeutics Inc. and VYNE Therapeutics Inc. | 10-K | 001-38356 | 10.19 | March 6, 2025 | |
| 10.20 | Letter Agreement, dated August 15, 2025, by and between the Registrant and Tay Therapeutics Limited. | 10-Q | 001-38356 | 10.1 | November 06, 2025 | |
| 10.21 | Form of Company Support Agreement. | 8-K | 001-38356 | 10.1 | December 17, 2025 | |
| 10.22 | Form of Yarrow Support Agreement | 8-K | 001-38356 | 10.2 | December 17, 2025 | |
| 10.23 | Form of Securities Purchase Agreement | 8-K | 001-38356 | 10.3 | December 17, 2025 | |
| 10.24 | Form of Registration Rights Agreement | 8-K | 001-38356 | 10.4 | December 17, 2025 | |
| 10.25 | Form of Lock-Up Agreement | 8-K | 001-38356 | 10.5 | December 17, 2025 | |
| 19 | Insider Trading Policy | 10-K | 001-38356 | 19 | March 06, 2025 | |
| 21.1 | List of Subsidiaries of VYNE Therapeutics Inc. | X | ||||
| 23.1 | Consent of independent registered public accounting firm. | X | ||||
| 24.1 | Power of Attorney (included on signature page). | X | ||||
| 31.1 | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 31.2 | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.1** | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.2** | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 97.1# | VYNE Therapeutics Inc. Incentive Compensation Recoupment Policy, dated November 8, 2023. | 10-K | 001-38356 | 97.1 | March 1, 2024 | |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | XBRL Taxonomy Extension Schema Document | X | ||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | X | ||||
| 101.DEF | XBRL Taxonomy Extension Definition Document | X | ||||
| 101.LAB | XBRL Taxonomy Extension Label Document | X | ||||
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document | X | ||||
| 104 | Cover Page Interactive Data Filed (embedded within the XBRL document) | |||||
- Exhibits and schedules omitted pursuant to Item 601(a)(5) of Regulation S-K.
^ Schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.
† Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.